- Data from the Company’s Actimab-A program to be presented in the Clinical Experiences session
being held on Wednesday, May 31, 2017
- Actinium is a sponsor of the conference being held May 30th - June 2nd , 2017
at Kanazawa University in Kanazawa, Japan
- Representatives from Actinium’s business development, clinical and executive teams to attend
NEW YORK, May 23, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the
Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, announced today that data from the Company’s Actimab-A program will be presented in an oral presentation at the
10th International Symposium on Targeted Alpha Therapy (TAT10) being held on May 30 – June 2, 2017 at Kanazawa
University in Kanazawa, Japan. Actinium’s Actimab-A drug candidate is a targeted radioimmunotherapy that consists of the alpha
emitting radioisotope actinium-225 linked to an anti-CD33 monoclonal antibody. Actimab-A is currently being studied in a
53-patient, open label, multicenter Phase 2 clinical trial in patients newly diagnosed with acute myeloid leukemia (AML) who are
age 60 and above.
Dr. Mark Berger, Actinium’s Chief Medical Officer said, “I very much look forward to presenting data from our
Actimab-A program at the symposium. Given its specific focus on alpha particle based therapies, I can think of no better venue to
showcase Actimab-A. I am confident that symposium attendees will be excited to hear about Actimab-A’s potential in acute myeloid
leukemia, where our studies have shown a promising safety and efficacy profile in this difficult to treat hematologic indication.
The powerful alpha particles enable Actimab-A activity in an indication where traditional oncology agents have not been able to
produce effective results.”
Additional information about TAT-10 can be found via the symposium’s link:
http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/
Details on Actinium’s oral presentation are below:
Date: Wednesday, May 31, 2017
Session: Clinical Experiences
Title: Efficacy of 225Ac-labeled anti-CD33 antibody in acute myeloid leukemia (AML) correlates with
peripheral blast count
Actinium’s Executive Chairman Sandesh Seth said, “Actinium is excited to once again be a sponsor of the
International Symposium on Targeted Alpha Therapy. This conference has become the leading scientific forum and a key event in the
field of alpha particle based targeted therapies. The symposium brings together thought leaders in the field from the
pharmaceutical industry, government agencies and academic based researchers who continue to advance the field and establish alpha
radiation as an effective therapeutic modality. As evidenced by the quality of the scientific, technological and clinical
abstracts, this year’s symposium is an excellent showcase for the promise that alpha based therapies hold based on their
differentiated biological profile compared to other forms of radiation and our team is looking forward to presenting Actimab-A and
meeting with symposium attendees.”
About Actimab-A
Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) product candidate, is currently in a
53-patient, multicenter Phase 2 trial for patients newly diagnosed with AML age 60 and above. Actimab-A is being developed as a
first-line therapy and is a monotherapy that is administered via two 15-minute injections that are given 7 days apart. Actimab-A
targets CD33, a protein abundantly expressed on the surface of AML cells via the monoclonal antibody, HuM195, which carries the
potent cytotoxic radioisotope actinium-225 to the AML cancer calls. Actinium-225 gives off high-energy alpha particles as it
decays, which kill cancer cells and as actinium-225 decays it produces a series of daughter atoms, each of which gives off its own
alpha particle, increasing the chances that the cancer cell will be destroyed. Actimab-A is a second-generation therapy from the
Company’s HuM195-Alpha program, which was developed at Memorial Sloan Kettering Cancer Center and has now been studied in over 90
patients in four clinical trials. Actimab-A has been granted Orphan Drug Designation for newly diagnosed AML in patients 60 and
above by the U.S. Food and Drug Administration and the European Medicines Agency.
About Actinium’s Alpha Particle Immunotherapy Platform
Actinium's Alpha Particle Immunotherapy (APIT) platform is a highly potent and selective form of targeted
payload radioimmunotherapy. The APIT platform is based on attaching the powerful alpha emitting radioisotope Actinium-225 to
monoclonal antibodies (mAbs), which are large molecules capable of binding specifically to cancer cells. By virtue of carrying
alpha emitters, mAbs bring Actinium-225 directly to cancer cells where alpha emitters can selectively kill the targeted cell.
Actinium-225 emits significant energy making it a potent against targeted cancer cells but this energy only travels extremely short
distances limiting damage to healthy tissues. Due to the targeting of this energy by way of the mAbs bringing the alpha emitting
isotopes directly to cancer cells, Actinium believes Actinium-225 enabled therapies will result in potentially more effective and
at the same time tolerable therapies.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for
patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to
deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product
candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly
referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne
cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in
significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow
transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal
150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age
55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial
for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with
AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition,
Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1
clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug
candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form
solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit
www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause
actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and
actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: Actinium Pharmaceuticals, Inc. Steve O'Loughlin Vice President, Finance and Corporate Development soloughlin@actiniumpharma.com